- Trial phase
- Approved
- Time to market
- Already marketed, approved since 1988 (Sandostatin) and 1998 (Sandostatin LAR)
- Why 2/10
- No hard, dated catalyst is scheduled in the next ~12 months: Sandostatin was approved in 1988 and Sandostatin LAR in 1998, both decisions passed decades ago, and the drug is a small legacy product within a ~$57B-revenue company, so impactScore stays at 2.
Treat Sandostatin as immaterial to NVS: it is an approved, generics-eroded legacy drug with no scheduled binary catalyst, so it should not drive a trade. For anyone holding NVS, the stock's move will be set by the broader pipeline and earnings (consensus rating 'hold', mean price target $157.15 vs. ~$156.24 spot, per local analyst data), not by this product.
Price Chart
Executive Summary
Sandostatin (octreotide, marketed with the long-acting depot form Sandostatin LAR) is a decades-old somatostatin-analog drug from Novartis (NYSE: NVS) used to treat acromegaly and symptoms of neuroendocrine/carcinoid tumors. It is fully approved and commercialized, FDA approval catalysts are recorded locally for Sandostatin (1988-10-21) and Sandostatin LAR (1998-11-25), and is a mature, generic-eroded legacy product rather than a growth or binary-catalyst asset.
How It Works
Octreotide is a synthetic copy of somatostatin, a natural hormone that tells the body to slow down secretion of growth hormone and several digestive hormones. By mimicking somatostatin, it blocks excess hormone production, which is why it is used to treat acromegaly (excess growth hormone) and to control flushing/diarrhea and tumor hormone output in neuroendocrine and carcinoid tumors. Sandostatin LAR is a slow-release depot version given by injection about once a month instead of several times a day.
Trial Status
No active Novartis development on Sandostatin itself: local trial records show a Novartis Phase 3 in diabetic retinopathy (NCT00248157) was terminated in 2006 for "inconsistent treatment benefit," and an investigator-led Phase 3 combining Sandostatin LAR with axitinib in non-pancreatic neuroendocrine tumors (NCT01744249) is COMPLETED. The main competitive development is a next-generation octreotide subcutaneous depot (CAM2029) whose Phase 3 acromegaly trial (NCT04076462) is COMPLETED.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for Sandostatin itself, no PDUFA, readout, or label decision in the next 12 months.
- NVS quarterly earnings: watch legacy-portfolio sales trends (Sandostatin erosion) as a minor line item.
- Competitor next-gen octreotide depot (CAM2029) commercialization/regulatory steps in acromegaly, which would further pressure the category.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report